Based in Cranbury, NJ, VaxInnate specializes in developing vaccines for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. Their technology platform improves vaccine potency, manufacturing capacity, and cost-effectiveness. Positive clinical data has been generated for their seasonal and pandemic vaccines, showing excellent potency in the elderly population. By genetically fusing vaccine antigens to the bacterial protein flagellin, VaxInnate's vaccines enhance immunogenicity and efficacy, leading to faster treatment and higher success rates. Founded in 2002, VaxInnate is focused on revolutionizing vaccine development in the healthcare and biotechnology sectors.